#Switzerland #Spinal Cord Injury #NovaGo Therapeutics #Schlieren #Nogo-A Biologics

NovaGo Therapeutics Secures $30 Million in Series B Financing

In a significant advancement for spinal cord injury treatment, NovaGo Therapeutics AG has successfully completed a CHF 24 million (USD 30 million) Series B funding round. This financing, which was led by Neurimmune and Pureos, attracted both existing and new investors, and received additional non-dilutive support from the Swiss Paraplegic Foundation and Wings for Life - Spinal Cord Research Foundation.

Purpose of the Funding

The funds will be directed towards propelling NovaGo's lead program into a proof-of-concept (PoC) study targeting acute spinal cord injury. The clinical trial, which is fully randomized and double-blind, aims to enroll 120 patients across Germany, Spain, and Switzerland. This study is particularly crucial as it addresses a significant healthcare gap; currently, there are no approved regenerative treatments that restore lost neurological functions following such injuries.

Understanding the Science Behind NovaGo’s Approach

At the heart of NovaGo's therapeutic strategy is the targeting of Nogo-A, a protein that impedes nerve fiber regeneration and neuroplasticity within the central nervous system. By inhibiting this protein, the hope is to facilitate functional recovery in affected individuals.

Chief Scientific Officer Prof. Martin Schwab expressed excitement about reaching this critical juncture in clinical testing, emphasizing the potential for providing much-needed therapies for patients grappling with the aftermath of spinal cord injuries. Prof. Roger M. Nitsch, President and CEO of Neurimmune, stated that this collaboration marks a pioneering effort to leverage a fully human therapeutic antibody to foster nerve outgrowth post-injury.

Support and Encouragement from the Investment Community

Dominik Escher, Managing Partner at Pureos Bioventures, communicated confidence in the potential of Nogo-A antibodies for offering a novel regenerative treatment. The promising Phase 1 results of the candidate NG004 have encouraged continued investment and support for the next phases of NovaGo's development.

CEO Stefan Moese highlighted the significance of investor backing, stating that their commitment plays a fundamental role in advancing towards a transformative treatment option for patients affected by spinal cord injuries. The support from leading foundations illustrates the collective aim towards enhancing therapeutic prospects in this challenging area of medicine.

What Lies Ahead

The path forward for NovaGo Therapeutics appears promising, with its strategic focus on developing innovative therapies for central nervous system-related injuries. With the backing of experienced investors and a compelling scientific approach, there is hope that this clinical development could ultimately lead to impactful changes in how spinal cord injuries are treated. As they continue into this pivotal phase of research, both the medical community and patients look onward to potential breakthroughs in regenerative medicine that could drastically change lives.

In summary, NovaGo's successful financing is a substantial step towards the realization of effective treatments for spinal cord injuries, marking an encouraging phase in the domain of clinical biotechnology.